Myasthenia gravis with myositis induced by pembrolizumab therapy in a patient with metastatic urothelial carcinoma
Author:
Publisher
Springer Science and Business Media LLC
Link
http://link.springer.com/content/pdf/10.1007/s13691-020-00408-4.pdf
Reference14 articles.
1. Kubota Y, Nakaigawa N, The Committee for Establishment of the Clinical Practice Guideline for the Management of Bladder Cancer, and the Japanese Urological Association (2016) Essential content of evidence-based clinical practice guidelines for bladder cancer: the Japanese Urological Association 2015 update. Int J Urol 23:640–645
2. von der Maase H, Hansen SW, Roberts JT et al (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer : results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18:3068–3077
3. Suzuki S, Ishikawa N, Konoeda F et al (2017) Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology 89:1127–1134
4. Alnahhas I, Wong J (2017) A case of new-onset antibody-positive myasthenia gravis in a patient treated with pembrolizumab for melanoma. Muscle Nerve 55:E25–E26
5. March KL, Samarin MJ, Sodhi A et al (2018) Pembrolizumab-induced myasthenia gravis: a fatal case report. J Oncol Pharm Pract 24:146–149
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Pembrolizumab-Induced Myasthenia Gravis: A Case Report and Review of the Literature;Cureus;2023-06-28
2. Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature;ESMO Open;2023-02
3. Exploring the role of immune checkpoint inhibitors in the etiology of myasthenia gravis and Lambert-Eaton myasthenic syndrome: A systematic review;Frontiers in Neurology;2023-01-09
4. Pembrolizumab-Induced Myasthenia Gravis and Myositis: Literature Review on Neurological Toxicities of Programmed Death Protein 1 Inhibitors;Journal of Medical Cases;2022-11
5. Treatment of patients with cancer using PD‑1/PD‑L1 antibodies: Adverse effects and management strategies (Review);International Journal of Oncology;2022-04-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3